Treatment News : ViiV Files Regulatory Applications for New Integrase Inhibitor Dolutegravir

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » December 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

December 18, 2012

ViiV Files Regulatory Applications for New Integrase Inhibitor Dolutegravir

ViiV Healthcare announced it has filed regulatory applications for the company’s investigational HIV integrase inhibitor dolutegravir in the United States, Canada and the European Union. The applications seek approval for the new drug to treat HIV among people 12 and older. ViiV has submitted its applications to the U.S. Food and Drug Administration (FDA), Health Canada and the European Medicines Agency.

The pharmaceutical company recently presented Phase III clinical trial data showing dolutegravir (S/GSK1349572) was effective at treating patients with multidrug resistance—specifically, resistance to the integrase inhibitors raltegravir and/or elvitegravir. The drug maintains a relatively low side effect profile, and only 3 percent of study participants discontinued because of adverse effects.

In a statement, ViiV’s chief scientific and medical officer John Pottage, MD, said, “We are encouraged by the comprehensive data package supporting dolutegravir, and believe that it has the potential to offer an important new option for the treatment of both naive and treatment-experienced patients with HIV.”

To read the ViiV release, click here.

Search: HIV, ViiV Healthcare, regulatory application, integrase inhibitor, dolutegravir, U.S. Food and Drug Administration, FDA, , Health Canada, European Medicines Agency, S/GSK1349572, raltegravir, elvitegravir, low side effect profile, John Pottage, treatment-naive, treatment-experienced.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


         


[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Have you ever been diagnosed with diabetes or pre-diabetes?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.